Aurobindo Pharma Limited — Board Meeting, 26-05-2025: Outcome of Board Meeting

Aurobindo Pharma has announced a board meeting that approved the consolidated financial results for the quarter and year ended March 31, 2025. The group posted revenue of ₹3,17,237.3 million and a profit after tax of ₹34,835.7 million for the year. Earnings per share came in at ₹59.81. The board plans to seek shareholder approval via postal ballot to raise existing investment limits. MRR & Associates is appointed as Secretarial Auditors for five years starting FY 2025-26, pending shareholder nod. The company also completed a ₹930.24 Cr share buyback during the year.